BHRT vs. FDA-Approved Hormone Therapy: What Clinic Owners Need to Know

The Formulary Decision That Determines Your Clinical Credibility and Your Liability Exposure

The Distinction Clinic Marketing Often Gets Wrong

Ask many patients what bioidentical hormone therapy means and they will say compounded. Ask many clinic websites and they will imply the same thing. Both are wrong, and the error is commercially consequential.

Bioidentical describes molecular structure: a hormone with exactly the same chemical structure as the one the body produces. It says nothing about who manufactured it or under what oversight.

Many FDA-approved hormone preparations are bioidentical. As noted in the Endocrine Society's position statement, hormone therapy with structures identical to endogenous hormones is available as FDA-approved preparations including oral estradiol, transdermal estradiol patches, gels, sprays and lotions, estradiol vaginal creams, tablets, rings and inserts, and micronized oral or vaginal progesterone.

This means a clinic can offer bioidentical hormone therapy using FDA-approved, manufacturer-produced, retail-pharmacy-dispensed products. The choice is not between bioidentical and synthetic. It is between compounded and FDA-approved, and those carry very different oversight profiles.

Where the Major Societies Actually Stand

Clinic owners should know this before building a formulary, because patients increasingly arrive having read it.

The Endocrine Society's position is direct. Its statement on compounded bioidentical hormone therapy, reissued in 2019, says there is no evidence-based medical need for the use of compounded hormone therapy when an FDA-approved preparation is available. The FDA points the same way: many products marketed as bioidentical hormones are compounded drugs, which the FDA says are not FDA-approved; it does not have evidence that compounded "bioidentical hormones" are safe and effective, and recommends FDA-approved hormone therapy.

The Menopause Society's 2022 position statement identifies similar concerns with compounded bioidentical hormone therapy: minimal government regulation and monitoring, overdosing or underdosing, presence of impurities or lack of sterility, absence of scientific efficacy and safety data, and no label outlining risks.

FDA's rules leave narrow room for compounding a copy of an approved product. Under FDA's 2018 essentially-a-copy guidance, the exception for a compounded version of a commercially available drug depends on a prescriber's determination that a change produces a significant difference for an identified individual patient, such as an allergy to an ingredient in the approved formulation or a dose not available in any approved product. Where such a copy is prescribed, the guidance is to document that determination on the prescription.

The Pellet Question

Pellet therapy deserves specific attention because it is heavily marketed to clinic owners as a high-margin service and because the clinical literature is less favorable than the sales materials suggest.

The Endocrine Society position statement references a study of blood levels well above the anticipated range in women using compounded pellet therapy.

The operational concern compounds the clinical one: a pellet cannot be dose-adjusted or removed easily once implanted. In a therapy where individualized titration is the stated rationale for compounding in the first place, a delivery route that eliminates the ability to titrate is a genuine contradiction that clinic owners should think through rather than inherit from a vendor's pitch.

This is not a claim that no clinic should offer pellets. It is a claim that the decision deserves the medical director's independent clinical judgment rather than a margin calculation.

Salivary Testing

Compounded hormone dosing is frequently marketed alongside salivary hormone testing as the mechanism for personalization. The Endocrine Society's statement finds the claims made for salivary testing not supported by scientific data confirming assay quality control, standardization, or clinical correlations.

A clinic building its clinical differentiation on rigor should use serum testing and be prepared to explain why. A clinic using salivary testing because a vendor packaged it with a compounding relationship is building on a foundation that a well-informed patient (or an expert witness) will find easy to challenge.

The Formulary Position That Actually Differentiates

Here is the commercially useful insight in all of this. The competitive landscape in women's hormone health is crowded with clinics whose entire clinical proposition is compounded pellets and salivary testing. That is now the default, which means it differentiates nothing.

A clinic that builds its formulary primarily on FDA-approved bioidentical preparations, and uses compounding only where a documented clinical indication exists, occupies a position almost nobody else in the category is claiming. Approved products' labels are changing as well. In February 2026 the FDA approved the first label changes, removing the boxed-warning risk statements on cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy, after asking 29 drug companies to revise their labels; the changes are approved product by product, and the FDA is not seeking to remove the boxed warning for endometrial cancer for systemic estrogen-alone products.

That position is defensible clinically, aligned with the Endocrine Society's statement and the FDA's recommendation, and increasingly attractive to a patient population that has become more sophisticated about this exact question.

Sourcing and Documentation

Where a clinic does use compounded preparations for a documented indication, the same rules that govern all patient-specific compounding apply, under the 503A framework. The product must be compounded for an identified individual patient on receipt of a prescription, from a licensed pharmacy.

Practices should verify the pharmacy's licensing and accreditation status directly rather than relying on marketing materials, and should retain documentation of the clinical indication that justified compounding over an available FDA-approved alternative. That documentation is what distinguishes a considered clinical decision from a default formulary choice if the question is ever raised.

The medical director should review and approve the formulary in writing, including the specific circumstances under which compounded preparations will be used. A formulary assembled from vendor relationships without that review is a clinical decision made by a sales process. In ACG's launch program, that review is part of protocol setup for a new wellness clinic.

How to Have This Conversation With Patients

Patients arriving at a women's hormone clinic frequently ask for bioidentical hormones specifically, and often mean compounded when they say it. Handling that well matters.

The accurate and reassuring answer is that bioidentical describes molecular structure, that many FDA-approved products are bioidentical, and that the clinic can offer bioidentical therapy with the added benefit of manufacturing oversight for dose and purity. Many patients hear that as an upgrade rather than a refusal, because what they actually want is a hormone identical to what their body produces, which is exactly what they get.

Where a patient specifically requests compounded therapy or pellets, the clinician should explain the considerations honestly and document the discussion. Patients who understand the reasoning generally accept the clinical recommendation. Those who insist on a specific product regardless of clinical rationale are, in many cases, patients a clinic is better off not enrolling.

For how our team helps founders launch a hormone clinic, see what it takes to open a women's health and menopause clinic, or to open a hormone optimization and HRT clinic. To discuss formulary strategy for your clinic, book a free 30-minute strategy call.

Frequently Asked Questions

Does bioidentical mean compounded?

No. Bioidentical describes molecular structure: identical to hormones the body produces. Many FDA-approved products are bioidentical, including oral and transdermal estradiol and micronized progesterone. Compounding refers to who prepares the product and under what oversight. Conflating the two is a common error in clinic marketing.

When is compounded hormone therapy clinically appropriate?

FDA's essentially-a-copy guidance leaves narrow room for compounding a copy of an FDA-approved product, resting on a prescriber's documented determination that a change produces a significant difference for an identified individual patient, such as an allergy to an ingredient in an FDA-approved formulation or a dose not commercially available. In 2020 the National Academies advised prescribers to limit compounded bioidentical hormones to patients allergic to an approved product's ingredient or needing a dosage form approved products lack. Where prescribed, the clinical indication should be documented rather than assumed. Compounding as a default formulary choice, absent one of these indications, is not supported by current guidance.

Should my clinic offer pellet therapy?

That is a decision for the medical director based on independent clinical judgment. Clinic owners should be aware of the study, cited by the Endocrine Society, of blood levels well above the anticipated range in women using compounded pellets, and of the practical inability to titrate or remove a pellet after implantation.

Are FDA-approved products more expensive for patients?

Not necessarily, and less so than clinic owners often assume. Coverage varies and many products have manufacturer savings programs. The FDA also approved a generic conjugated estrogens product as part of the menopausal hormone therapy actions HHS announced in November 2025. Clinics should verify current pricing rather than relying on assumptions formed several years ago.